For the quarter ending 2026-03-31, RAPP had -$169,143K decrease in cash & cash equivalents over the period. $50,072K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Net loss | 57,863 | -26,925 | -50,795 |
| Depreciation and amortization | -525 | 256 | 496 |
| Non-cash loss on sale of property and equipment | 153 | - | - |
| Net (accretion) and amortization of investments in marketable securities | 40 | -204 | 528 |
| Non-cash lease expense | -879 | 567 | 894 |
| Stock-based compensation expense | -6,201 | 4,735 | 8,429 |
| Accounts receivable | 58 | - | - |
| Prepaid expenses and other current assets | -3,424 | -2,534 | 5,144 |
| Other assets | -1,256 | 362 | 548 |
| Accounts payable | 1,268 | -179 | 1,216 |
| Accrued expenses and other current liabilities | -5,971 | 1,696 | 784 |
| Operating lease liabilities | 579 | -9 | 111 |
| Net cash used in operating activities | 49,711 | -17,465 | -45,307 |
| Purchases of short-term investments | -127,343 | 101,620 | 56,093 |
| Sale of short-term investments | 10,075 | - | - |
| Maturities of short-term investments | -86,689 | 44,978 | 100,033 |
| Purchases of property and equipment | -361 | 134 | 313 |
| Net cash provided by investing activities | 51,090 | -56,776 | 43,627 |
| Proceeds from underwritten public offering, net of underwriter discounts and commissions and deferred offering costs | - | 269,834 | - |
| Payment of deferred offering costs | 210 | - | 63 |
| Proceeds from exercise of stock options | 167 | 636 | 6 |
| Repurchase of unvested restricted common stock | 4 | 0 | 1 |
| Net cash provided by financing activities | -269,944 | 270,533 | -58 |
| Net increase in cash, cash equivalents, and restricted cash | -169,143 | 196,292 | -1,738 |
| Cash, cash equivalents, and restricted cash at beginning of period | 251,464 | 56,910 | - |
| Cash, cash equivalents, and restricted cash at end of period | 78,161 | 251,464 | - |
Rapport Therapeutics, Inc. (RAPP)
Rapport Therapeutics, Inc. (RAPP)